RApid Diagnosis of Infections in the CriticAlly IlL
Research type
Research Study
Full title
A multicenter observational study to compare Polymerase Chain Reaction/Electrospray Ionization – Mass Spectrometry (PCR/ESI-MS) results to conventional clinical and microbiological evaluation and/or sequencing in critically ill patients with suspected severe infections.
IRAS ID
134477
Contact name
Mervyn Singer
Contact email
Sponsor organisation
Ibis Biosciences Inc, An Abbott Company
Research summary
This is an observational study to compare the performance of Polymerase Chain Reaction/Electrospray Ionization-Mass Spectrometry (PCR/ESI-MS) technology to conventional clinical and microbiological evaluation and/or sequencing in critically ill patients with clinical signs and symptoms of severe infections. The study will focus on critically ill patients with sepsis, severe pneumonia, and other infections who require critical care assessment and evaluation. Patients with severe infections are likely to benefit from the rapid and accurate assessment of infectious pathogens and the associated institution of appropriate antimicrobial therapy. PCR/ESI-MS technology is a new approach to microbial identification that has the potential to provide diagnostic information regarding infectious pathogens more quickly than current microbiological testing. PCR/ESI-MS has been studied in multiple settings but its benefit in the critically ill population with suspected severe infections has not been assessed to date
REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
13/NW/0598
Date of REC Opinion
15 Oct 2013
REC opinion
Further Information Favourable Opinion